About Us

Investing in Israel.

Health-tech has come of age. But investing in healthcare innovation is not like other sectors: Entrepreneurs need active expert guidance to transition their ideas into scalable and successful healthcare solutions.

Israel is an established powerhouse of technological innovation, and ANOVA maximizes Israeli opportunities by addressing both local knowledge gaps and capital gaps while creating a mechanism to support commercialization

The paths toward meaningful exits & financial returns are clear, but capitalizing on the potential returns requires addressing three key components:

Capital Gap

Clear need for smart seed funding for the most promising pilot-ready startups in Israel

Knowledge Gap

Extensive understanding of healthcare economics, business models, operations, processes, workflows, integration, and strategy – who pays for what and why

Access Gap

Global network of partners who articulate actual rather than perceived needs and support portfolio companies through initial international expansion and growth

ANOVA helps portfolio companies addresses the three main commercialization barriers:

Reduce time to first pilot

Reduce time to first customer

Reduce time to ARR

ANOVA in action.

Local Israeli ecosystem

Robust network of local ecosystem partners for deal flow: Angels, HMOs, health orgs, VC’s at all stages, corporate stakeholders, Incubators, accelerators

ANOVA

Critical seed-stage support for companies with potential for large scale commercialization; investing capital and time where our expertise and network can make the largest impact

Commercialization relationships

Robust network of corporate multinationals and leading international healthcare organizations support pilots and first commercialisation efforts

Our strategic partnerships.

In addition to our broad network, we leverage our exclusive strategic partnerships at both ends of the funnel:

  • HealthIL provides insight and assessment of pilot-ready projects curated from across the Israeli ecosystem

  • Science Center of Philadelphia provides a early commercialization access for our portfolio companies